RAMM Pharma

RAMM Pharma EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of RAMM Pharma (RAMM.CN) as of Nov 2, 2026 is -0.42. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -0.32 — a change of 30.06% (lower).

EV/EBITDA

-0.42

YoY

30.06%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of RAMM Pharma is 2025 -0.42 . EV/EBITDA (Enterprise Value to EBITDA) of RAMM Pharma was 2024 -0.32 . It decreases by 30.06% lower compared to the previous year.

The RAMM Pharma EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
9.49 CAD
Jan 1, 2019
-0.32 CAD
Jan 1, 2020
-0.24 CAD
Jan 1, 2021
-0.30 CAD
Jan 1, 2022
-0.26 CAD
Jan 1, 2023
-0.31 CAD
Jan 1, 2024
-0.32 CAD
Jan 1, 2025
-0.42 CAD
The RAMM Pharma EV/EBITDA history
YEAREV/EBITDAYoY
-0.42+30.06%
-0.32+3.39%
-0.31+20.27%
-0.26-14.31%
-0.30+27.38%
-0.24-27.04%
-0.32-103.41%
9.49—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RAMM Pharma Stock analysis

What does RAMM Pharma do? RAMM Pharma Corp generates revenue through cannabinoid pharmaceuticals and cannabis-based products, with brands like NettaLife, NettaPet, NettaPet Senior, NettaPet Puppies, and NettaVet targeting pet owners and veterinary markets. The company also sells cosmetics under the Cannabipiel line, including Cannabipiel Nite, Cannabipiel Body Lotion, and Cannabipiel Shampoo, catering to consumers seeking cannabinoid-infused skincare and personal care solutions. Subsidiaries such as Canapar Corp. and Medic Plast SA support production and commercialization across pharmaceutical specialties, household products, and food sectors. The firm’s product portfolio spans pharmaceuticals, pet care, cosmetics, and household items, with NettaPet and NettaVet focusing on animal health and Cannabipiel products targeting human skincare. Revenue streams include direct sales of branded items like Cannabipiel Tite and Cannabipiel Cleaning Emulsion to retail and specialty markets, while subsidiaries handle manufacturing and export operations for global distribution. Brands like Glediser SA and Yurelan SA contribute to the commercialization of diverse product categories under the company’s umbrella. RAMM Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RAMM Pharma stock

EV/EBITDA (Enterprise Value to EBITDA) of RAMM Pharma is -0.42 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of RAMM Pharma changed from -0.32 to -0.42, representing a 30.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) RAMM Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s RAMM Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — RAMM Pharma

All Key Metrics — RAMM Pharma